 Advances Phase 11b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to 67.5 million; Amends Non-Dilutive Term Loan Agreement SEATTLE, WA ACCESSWIRE March 31, 2021 Aptevo Therapeutics Inc. NASDAQ:APVO, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today reported its financial results for the year ended December 31, 2020, provided a clinical update, announced the sale of RUXIENCE royalty payments and responded to an indication of interest from Tang Capital Partners, LP TCP. We are very pleased with our performance in 2020 and believe we are well positioned for 2021 and beyond. 